#105 $INO Inovio Fast Track Dream or Regulatory Reality

In this episode of Sue Wall Street Holding Wall Street Accountable, we break down the securities class action involving $INO Inovio Pharmaceuticals and its accelerated approval hopes for INO 3107 and the CELLECTRA device. We examine the Biologics License Application delay, manufacturing issues, FDA standard review decision, stock offerings, and the twenty four percent stock drop that followed. This deep dive is for biotech investors, healthcare traders, and anyone following FDA approvals, DNA medicines, regulatory risk, and securities litigation news. Visit ZLK.com for more info. Add our WhatsApp Channel. We’re not lawyers or accountants, so don’t take this as legal or financial advice.